Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: britschgi m. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Specific immune modulation of experimental colitis drives enteric alpha-synuclein accumulation and triggers age-related Parkinson-like brain pathology.
Grathwohl S, Quansah E, Maroof N, Steiner JA, Spycher L, Benmansour F, Duran-Pacheco G, Siebourg-Polster J, Oroszlan-Szovik K, Remy H, Haenggi M, Stawiski M, Selhausen M, Mailver P, Wolfert A, Emrich T, Madaj Z, Su A, Escobar Galvis ML, Mueller C, Herrmann A, Brundin P, Britschgi M. Grathwohl S, et al. Among authors: britschgi m. Free Neuropathol. 2021 May 18;2:2-13. doi: 10.17879/freeneuropathology-2021-3326. eCollection 2021 Jan. Free Neuropathol. 2021. PMID: 37284635 Free PMC article.
A bottom-up approach identifies the antipsychotic and antineoplastic trifluoperazine and the ribose derivative deoxytubercidin as novel microglial phagocytosis inhibitors.
Rodriguez-Iglesias N, Paris I, Valero J, Cañas-Zabala L, Carretero A, Hatje K, Zhang JD, Patsch C, Britschgi M, Gutbier S, Sierra A. Rodriguez-Iglesias N, et al. Among authors: britschgi m. Glia. 2025 Feb;73(2):330-351. doi: 10.1002/glia.24637. Epub 2024 Nov 4. Glia. 2025. PMID: 39495090 Free PMC article.
Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
Moors TE, Mona D, Luehe S, Duran-Pacheco G, Spycher L, Mundigl O, Kaluza K, Huber S, Hug MN, Kremer T, Ritter M, Dziadek S, Dernick G, van de Berg WDJ, Britschgi M. Moors TE, et al. Among authors: britschgi m. Acta Neuropathol Commun. 2022 Jun 3;10(1):82. doi: 10.1186/s40478-022-01382-z. Acta Neuropathol Commun. 2022. PMID: 35659116 Free PMC article.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: britschgi m. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Epigenetic inactivation of the autophagy-lysosomal system in appendix in Parkinson's disease.
Gordevicius J, Li P, Marshall LL, Killinger BA, Lang S, Ensink E, Kuhn NC, Cui W, Maroof N, Lauria R, Rueb C, Siebourg-Polster J, Maliver P, Lamp J, Vega I, Manfredsson FP, Britschgi M, Labrie V. Gordevicius J, et al. Among authors: britschgi m. Nat Commun. 2021 Aug 26;12(1):5134. doi: 10.1038/s41467-021-25474-x. Nat Commun. 2021. PMID: 34446734 Free PMC article.
The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
Moors TE, Maat CA, Niedieker D, Mona D, Petersen D, Timmermans-Huisman E, Kole J, El-Mashtoly SF, Spycher L, Zago W, Barbour R, Mundigl O, Kaluza K, Huber S, Hug MN, Kremer T, Ritter M, Dziadek S, Geurts JJG, Gerwert K, Britschgi M, van de Berg WDJ. Moors TE, et al. Among authors: britschgi m. Acta Neuropathol. 2021 Sep;142(3):423-448. doi: 10.1007/s00401-021-02329-9. Epub 2021 Jun 11. Acta Neuropathol. 2021. PMID: 34115198 Free PMC article.
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset.
Gries M, Christmann A, Schulte S, Weyland M, Rommel S, Martin M, Baller M, Röth R, Schmitteckert S, Unger M, Liu Y, Sommer F, Mühlhaus T, Schroda M, Timmermans JP, Pintelon I, Rappold GA, Britschgi M, Lashuel H, Menger MD, Laschke MW, Niesler B, Schäfer KH. Gries M, et al. Among authors: britschgi m. Mol Neurodegener. 2021 Jun 2;16(1):34. doi: 10.1186/s13024-021-00439-2. Mol Neurodegener. 2021. PMID: 34078425 Free PMC article.
69 results